# Karxt PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/karxt

> The next catalyst for karxt, sponsored by BRISTOL MYERS SQUIBB CO (BMY), is its primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | karxt |
| Codes | BMS-986510 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [Psychosis Associated With Alzheimer's Disease](https://sec-api.dev/indications/psychosis-associated-with-alzheimer-s-disease), [Schizophrenia](https://sec-api.dev/indications/schizophrenia), [Irritability Associated With Autism Spectrum Disorder](https://sec-api.dev/indications/irritability-associated-with-autism-spectrum-disorder), [Alzheimer's Disease](https://sec-api.dev/indications/alzheimer-s-disease), [Bipolar-I Disorder With Mania or Mania With Mixed Features](https://sec-api.dev/indications/bipolar-i-disorder-with-mania-or-mania-with-mixed-features), [Bipolar Disorder Type I With Mania](https://sec-api.dev/indications/bipolar-disorder-type-i-with-mania), [Alzheimer Disease](https://sec-api.dev/indications/alzheimer-disease), [Bipolar Disorder Type I With Mania or Mania With Mixed Features](https://sec-api.dev/indications/bipolar-disorder-type-i-with-mania-or-mania-with-mixed-features) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Psychosis Associated With Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05511363 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-10-05 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT05511363

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Psychosis Associated With Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05511363 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-10-05 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT05511363

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alzheimer Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06585787 (A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT06585787

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Bipolar-I Disorder With Mania or Mania With Mixed Features.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06951698 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06951698

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Bipolar-I Disorder With Mania or Mania With Mixed Features.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06951698 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06951698

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Bipolar Disorder Type I With Mania or Mania With Mixed Features.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06951711 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06951711

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Bipolar Disorder Type I With Mania or Mania With Mixed Features.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06951711 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06951711

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alzheimer Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06585787 (A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT06585787

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Psychosis Associated With Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06126224 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-09 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT06126224

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Psychosis Associated With Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06126224 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-09 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT06126224

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Psychosis Associated With Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05980949 (Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-07 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT05980949

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Psychosis Associated With Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05980949 (Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-07 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT05980949

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alzheimer Disease; Psychosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06947941 (A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-21 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06947941

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alzheimer Disease; Psychosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06947941 (A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-21 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06947941

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Bipolar Disorder Type I With Mania.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06929273 (A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06929273

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Bipolar Disorder Type I With Mania.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06929273 (A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06929273

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06882785 (A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-23 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06882785

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06976203 (A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06976203

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06976216 (A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06976216

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06976203 (A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06976203

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06976216 (A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-11 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06976216

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06882785 (A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-23 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06882785

### Jun to Sep 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alzheimer Disease; Agitation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06937229 (A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-22 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06937229

### June 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alzheimer Disease; Agitation.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06937229 (A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-22 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06937229

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Irritability Associated With Autism Spectrum Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07284745 (A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07284745

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Irritability Associated With Autism Spectrum Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07285798 (A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07285798

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Irritability Associated With Autism Spectrum Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07284745 (A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07284745

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Irritability Associated With Autism Spectrum Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07285798 (A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07285798

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07288567 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07288567

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07288567 (A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07288567

### Mar to Jun 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Schizophrenia; Autism-Related Irritability.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07424404 (A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-08 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT07424404

### March 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Schizophrenia; Autism-Related Irritability.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07424404 (A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-08 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." https://clinicaltrials.gov/study/NCT07424404

## Same indication

- [[18f]pi-2620](https://sec-api.dev/pdufa/18f-pi-2620) (LNTH)
- [ALTO-101](https://sec-api.dev/pdufa/alto-101) (ANRO)
- [Anavex3-71 oral capsules](https://sec-api.dev/pdufa/anavex3-71-oral) (AVXL)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Cariprazine flexible dose](https://sec-api.dev/pdufa/cariprazine-flexible-dose) (ABBV)
- [Dn-tnf](https://sec-api.dev/pdufa/dn-tnf) (INMB)
- [Donanemab](https://sec-api.dev/pdufa/donanemab) (LLY)
- [Emraclidine](https://sec-api.dev/pdufa/emraclidine) (ABBV)
- [GSK4527226](https://sec-api.dev/pdufa/gsk4527226) (GSK)
- [GXV813](https://sec-api.dev/pdufa/gxv813) (NVS)
- [Igc-ad1-active](https://sec-api.dev/pdufa/igc-ad1-active) (IGC)
- [Fanapt® (iloperidone)](https://sec-api.dev/pdufa/iloperidone) (VNDA)
- [JNJ-63733657](https://sec-api.dev/pdufa/jnj-63733657) (JNJ)
- [JNJ-64042056](https://sec-api.dev/pdufa/jnj-64042056) (JNJ)
- [Lb-102 (50 mg tablet)](https://sec-api.dev/pdufa/lb-102) (LBRX)
- [Caplyta (lumateperone tosylate)](https://sec-api.dev/pdufa/lumateperone) (JNJ)
- [Mevidalen](https://sec-api.dev/pdufa/mevidalen) (LLY)
- [MK-1167](https://sec-api.dev/pdufa/mk-1167) (MRK)
- [ML-007C-MA](https://sec-api.dev/pdufa/ml-007c-ma) (MPLT)
- [Ml-007c-ma bid](https://sec-api.dev/pdufa/ml-007c-ma-bid) (MPLT)
- [NBI-1117567](https://sec-api.dev/pdufa/nbi-1117567) (NBIX)
- [NBI-1117568](https://sec-api.dev/pdufa/nbi-1117568) (NBIX)
- [NBI-1117570](https://sec-api.dev/pdufa/nbi-1117570) (NBIX)
- [Olz/sam](https://sec-api.dev/pdufa/olz-sam) (ALKS)
- [Primec](https://sec-api.dev/pdufa/primec) (NRSN)
- [Remternetug](https://sec-api.dev/pdufa/remternetug) (LLY)
- [Sabirnetug](https://sec-api.dev/pdufa/sabirnetug) (ABOS)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)
- [VHB937](https://sec-api.dev/pdufa/vhb937) (NVS)
- [Xanomeline and trospium chloride capsules](https://sec-api.dev/pdufa/xanomeline-and-trospium) (BMY)
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium) (BMY)

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10), [November 2026](https://sec-api.dev/fda-calendar/2026-11), [December 2026](https://sec-api.dev/fda-calendar/2026-12), [September 2027](https://sec-api.dev/fda-calendar/2027-09), [February 2028](https://sec-api.dev/fda-calendar/2028-02), [June 2028](https://sec-api.dev/fda-calendar/2028-06), [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/karxt.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Karxt PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/karxt

```bibtex
@misc{secapidev_pdufa_karxt_20261116,
  title        = {Karxt PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/karxt}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_karxt_20261116","title":"Karxt PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/karxt","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
